In April 2025, CRA’s Life Sciences Practice hosted the “Emergence of competitive rare diseases,” a roundtable discussion and insightful exchange that offered an array of perspectives on the evolution of the orphan drug (OD) landscape.
Expanding upon how the rare disease space has developed since early ODs were approved, roundtable participants assessed how commercialization strategies have been impacted as indications become more competitive.
Read more on the emergence of competitive rare diseases here.
